Outcomes of extremely preterm infants who participated in a randomised trial of dopamine for treatment of hypotension (the HIP trial) at 2 years corrected age

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023698%3A_____%2F25%3AN0000014" target="_blank" >RIV/00023698:_____/25:N0000014 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/27661989:_____/25:10003004 RIV/61988987:17110/25:A2603DQC RIV/00216208:11120/25:43928003 RIV/70883521:28150/25:63594521

Výsledek na webu

<a href="https://fn.bmj.com/content/110/6/542" target="_blank" >https://fn.bmj.com/content/110/6/542</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/archdischild-2024-327894" target="_blank" >10.1136/archdischild-2024-327894</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Outcomes of extremely preterm infants who participated in a randomised trial of dopamine for treatment of hypotension (the HIP trial) at 2 years corrected age

Popis výsledku v původním jazyce

Objective To determine survival and neurodevelopmental outcomes in the Hypotension in Preterm (HIP) trial.Design Prospective follow-up of infants enrolled in randomised controlled trial.Participants 58 infants born before 28 weeks of gestation with low mean arterial blood pressure.Intervention Random allocation to treatment of low blood pressure values with infusion of dopamine or placebo.Primary outcome Survival without neurodevelopmental impairment to 24 months corrected age (CA).Results The HIP trial stopped early due to logistic and recruitment difficulties. Outcomes were determined for 55 infants (27 in the dopamine group and 28 in the placebo group) at 24 months CA. Survival without impairment was present in 13 (48%) infants in the dopamine group and 7 (25%) infants in the placebo group (OR 2.79 (95% CI 0.89, 8.72); p=0.078). The components of the primary outcome were similarly distributed between the two arms. Mean Bayley composite scores and the frequency of somatic impairments did not differ significantly between groups but infants were shorter and lighter at 2 years of age after dopamine administration.Conclusion In this placebo-controlled trial of the treatment of hypotension in extremely preterm infants, dopamine administration did not increase survival without impairment at 2 years CA. However, the study was not sufficiently powered and a clinically important effect cannot be excluded. The role of inotropic medication in facilitating good outcomes requires further study.

Název v anglickém jazyce

Outcomes of extremely preterm infants who participated in a randomised trial of dopamine for treatment of hypotension (the HIP trial) at 2 years corrected age

Popis výsledku anglicky

Objective To determine survival and neurodevelopmental outcomes in the Hypotension in Preterm (HIP) trial.Design Prospective follow-up of infants enrolled in randomised controlled trial.Participants 58 infants born before 28 weeks of gestation with low mean arterial blood pressure.Intervention Random allocation to treatment of low blood pressure values with infusion of dopamine or placebo.Primary outcome Survival without neurodevelopmental impairment to 24 months corrected age (CA).Results The HIP trial stopped early due to logistic and recruitment difficulties. Outcomes were determined for 55 infants (27 in the dopamine group and 28 in the placebo group) at 24 months CA. Survival without impairment was present in 13 (48%) infants in the dopamine group and 7 (25%) infants in the placebo group (OR 2.79 (95% CI 0.89, 8.72); p=0.078). The components of the primary outcome were similarly distributed between the two arms. Mean Bayley composite scores and the frequency of somatic impairments did not differ significantly between groups but infants were shorter and lighter at 2 years of age after dopamine administration.Conclusion In this placebo-controlled trial of the treatment of hypotension in extremely preterm infants, dopamine administration did not increase survival without impairment at 2 years CA. However, the study was not sufficiently powered and a clinically important effect cannot be excluded. The role of inotropic medication in facilitating good outcomes requires further study.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30209 - Paediatrics

Projekt

—

Návaznosti

R - Projekt Ramcoveho programu EK

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION

ISSN

1359-2998

e-ISSN

1468-2052

Svazek periodika

110

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

542-547

Kód UT WoS článku

001407136600001

EID výsledku v databázi Scopus

2-s2.0-85216115865